ArticleBMC endocrine disorders2026
Diagnostic utility of morning serum cortisol in predicting short synacthen test outcomes in outpatients with suspected adrenal insufficiency.
Article in BMC endocrine disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAdrenal insufficiency (AI) often presents with non-specific symptoms such as fatigue, posing a diagnostic challenge in outpatient settings. While the 250 µg short Synacthen test (SST) remains the gold standard for assessing adrenal function, it may be resource-intensive and inconvenient. Morning serum cortisol (MSC) offers a potential alternative for initial screening, but its predictive value for SST outcomes in community-referred patients remains uncertain.
objectiveTo evaluate the correlation between MSC and SST outcomes in outpatients presenting with non-specific symptoms suggestive of AI, and to identify MSC thresholds predictive of normal SST.
methodsThis retrospective cross-sectional study analyzed 228 SSTs performed between 2006 and 2021 on adult outpatients without known endocrine disease. MSC was measured prior to 250 µg intravenous Synacthen administration, with cortisol levels re-assessed 30 min post-injection (Cort30). Pearson correlation and Receiver Operating Characteristic (ROC) curve analysis were used to assess associations and identify optimal MSC cutoffs for predicting normal SST, defined as Cort30 ≥ 18 µg/dL (500 nmol/L).
resultsThe mean MSC and Cort30 values were 9.4 ± 3.9 (259 ± 108 nmol/L) and 20.8 ± 7 µg/dL (574 ± 193 nmol/L), respectively. Applying ROC analysis, MSC threshold of 8.7 µg/dL (240 nmol/L) yielded the optimal performance, providing 83.2% sensitivity, 49.5% specificity, 69% PPV, 68.9% NPV, and 68.9% accuracy. Among patients with MSC ≥ 8.7 µg/dL (240 nmol/L), 83.2% had normal SST. MSC values of 3 µg/dL (83 nmol/L) and 15.5 µg/dL (428 nmol/L) demonstrated 100% sensitivity and 100% specificity for predicting normal SST, respectively.
conclusionIn patients referred from the community with non-specific symptoms, MSC measurement may provide a useful adjunct for evaluating adrenal function, especially when MSC results are at the extremes. CLINICAL TRIAL NUMBER: 0133-21-BNZ.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.